维奈克拉联合奥妥珠单抗对比布鲁顿酪氨酸激酶抑制剂一线治疗慢性淋巴细胞白血病的真实世界疗效比较
这项回顾性观察研究利用Optum Clinformatics Data Mart®数据库,纳入2019年1月至2022年9月接受一线维奈克拉联合奥妥珠单抗(VenO)或布鲁顿酪氨酸激酶抑制剂(BTKi)方案的成人慢性淋巴细胞白血病(CLL)患者,采用稳定逆概率加权平衡基线特征。共纳入1506例患者(VenO组203例,BTKi组1303例),VenO组中位随访12.6个月,BTKi组16.2个月。结果显示VenO在治疗持续时间、持续性和至下一治疗或死亡时间等有效性结局上优于BTKi方案。
要点
- VenO组中位治疗持续时间为12.3个月,持续率在预期一线固定治疗期内高于BTKi组。
- VenO组中位至下一治疗或死亡时间未达到,12个月时未转换治疗或死亡比例为87.1% vs 75.3%。
- 停药患者中,VenO组中位至停药时间11.7个月 vs BTKi组5.9个月,中位停药时间11.3个月 vs 4.3个月。
核心结论
- 在这项真实世界研究中,VenO相比BTKi为基础方案在一线CLL中与更好的有效性结局相关。
研究设计与样本
- 回顾性观察研究,使用Optum Clinformatics Data Mart®数据库,纳入2019年1月至2022年9月接受一线VenO或BTKi方案的成人CLL患者(≥2次门诊或≥1次住院索赔)。
- 共纳入1506例 eligible 患者,其中VenO组203例,BTKi组1303例;采用稳定逆概率加权平衡基线特征。
- VenO组中位随访12.6个月,BTKi组中位随访16.2个月。
主要发现
- VenO组中位治疗持续时间(DoT)为12.3个月;在预期一线固定治疗期内,VenO组持续性高于BTKi组。
- VenO组中位至下一治疗或死亡时间(TTNT-D)未达到;12个月时未转换治疗或死亡的患者比例VenO组为87.1%,BTKi组为75.3%。
- 在停药患者中,VenO组中位至停药时间为11.7个月,BTKi组为5.9个月;VenO组中位停药时间为11.3个月,BTKi组为4.3个月。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Real-world evidence comparing clinical outcomes between venetoclax and Bruton tyrosine kinase inhibitors (BTKis) in patients with frontline (1 L) chronic lymphocytic leukaemia (CLL) is lacking. We compared treatment effectiveness of 1 L venetoclax plus obinutuzumab (VenO) versus BTKi-based regimens. This retrospective observational study using Optum Clinformatics Data Mart® included adult patients with CLL (≥2 outpatient or ≥1 inpatient claim) who received VenO or BTKi-based regimens in 1 L (1/2019-9/2022). Baseline characteristics were balanced using stabilised inverse probability weighting. Outcomes included duration of therapy (DoT), persistence, time to next treatment or death (TTNT-D), and time off-treatment. Among 1506 eligible patients (VenO: 203; BTKi: 1303), the median follow-up duration was 12.6 (VenO) and 16.2 months (BTKi). Median DoT for VenO was 12.3 months; persistence remained higher in VenO versus BTKi through expected 1 L fixed treatment duration. Median TTNT-D was not reached for VenO; however, more VenO- versus BTKi-treated patients had not switched therapies/experienced death through Month 12 (87.1% vs. 75.3%). Among patients that discontinued, median time to discontinuation was 11.7 vs. 5.9 months for VenO versus BTKi and median time off-treatment was 11.3 vs. 4.3 months. In this real-world study, VenO was associated with better effectiveness outcomes than BTKi-based regimens in 1 L CLL.
引用
- Ghosh N, Manzoor BS, Fakhri B, et al. Real-world comparative effectiveness of venetoclax-obinutuzumab versus Bruton tyrosine kinase inhibitors for frontline chronic lymphocytic leukaemia. Br J Haematol. 2024. PMID: 39049159. doi:10.1111/bjh.19613
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。